, /PRNewswire/ -- The global autism spectrum disorder therapeutics market size is estimated to grow by from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.78% during the forecast period.
Increasing prevalence of asd is driving market growth, with a trend towards increasing interest in personalized medicine for treatment of ASD. However, stringent regulations on asd therapeutics and treatments poses a challenge. Key market players include ASSERTIO HOLDINGS INC.
, AutismSTEP, Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La Roche Ltd.
, Fraser, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier, Neurim Pharmaceuticals Ltd., Novartis AG, Oryzon Genomics SA, Otsuka Holdings Co.
Ltd., PaxMedica Inc., Q BioMed Inc.
, Scioto Biosciences Inc., Stalicla SA, Travere Therapeutics Inc., Yamo Pharmaceuticals LLC, and Zynerba Pharmaceuticals Inc.
. Get a detailed analysis on regions, market segments, customer landscape, and companies - Personalized medicine, which involves customized treatments based on individual patients' genetic, environmental, and lifestyle factors, is gaining traction in the autism spectrum disorder (ASD) therapeutics market. The complexity and diversity of ASD symptoms and severity make it challenging to develop effective medications for all individuals.
Genetic testing plays a crucial role in personalized medicine for ASD. Researchers are investigating genetic variants contributing to ASD and cr.
